Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.54 |
| ▸ | HMGCR | P04035 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467458 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015885 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015928 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL4223277 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL4224620 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL55675 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL161365 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015846 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015963 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL4212914 | 1.00 | PTPN7 (0.54) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295388-B2 | Methods of modulating gastrointestinal metabolites | DSM IP ASSETS B.V. (NL) | 2025-05-13 | — | — | US | claimed |
| US-20220125074-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-28 | — | — | US | claimed |
| EP-3876747-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2021-09-15 | — | — | EP | claimed |
| EP-1194396-B1 | SELECTED CYCLOHEXANE-1,3- AND 1,4-DICARBOXYLIC ACID ESTERS | BASF AG (DE) | 2005-11-09 | — | — | EP | claimed |
| US-12357668-B2 | Anticancer activity of Buddleja saligna compositions | UNIVERSITY OF PRETORIA (ZA) | 2025-07-15 | — | — | US | disclosed |
| US-20250212913-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-07-03 | — | — | US | disclosed |
| US-20250185692-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250185693-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250185694-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250186979-A1 | CATALYST SYSTEM AND PROCESS FOR THE PREPARATION OF ALPHA OLEFINS AND ALPHA OLEFIN-CONTAINING PRODUCTS FROM LONG-CHAIN PARAFFINS | PANNON EGYETEM (HU) | 2025-06-12 | — | — | US | disclosed |
| US-20250185695-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-12295388-B2 | Methods of modulating gastrointestinal metabolites | DSM IP ASSETS B.V. (NL) | 2025-05-13 | — | — | US | disclosed |
| US-20220088109-A1 | Anticancer Activity of Buddleja Saligna Compositions | UNIVERSITY OF PRETORIA (ZA) | 2022-03-24 | — | — | US | disclosed |
| EP-3914276-A1 | ANTICANCER ACTIVITY OF BUDDLEJA SALIGNA COMPOSITIONS | University Of Pretoria (ZA) | 2021-12-01 | — | — | EP | disclosed |
| CN-113645850-A | Methods of modulating gastrointestinal metabolites | 帝斯曼知识产权资产管理有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021183896-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP ASSETS, B.V. (NL) | 2021-09-16 | — | — | WO | disclosed |
| EP-3876747-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2021-09-15 | — | — | EP | disclosed |
| WO-2020152577-A1 | ANTICANCER ACTIVITY OF BUDDLEJA SALIGNA COMPOSITIONS | UNIVERSITY OF PRETORIA (ZA) | 2020-07-30 | — | — | WO | disclosed |
| CN-108290992-A | POLYURETHANE/UREA MATERIALS | 联邦科学和工业研究组织 | 2018-07-17 | — | — | CN | disclosed |
| EP-0748823-A1 | Catalyst composition and process for the production of olefinic polymers | NIPPON OIL CO. LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186979-A1 | CATALYST SYSTEM AND PROCESS FOR THE PREPARATION OF ALPHA OLEFINS AND ALPHA OLEFIN-CONTAINING PRODUCTS FROM LONG-CHAIN PARAFFINS | MAX, ECH1, PCNA | PTPN7 3547/4885HMGCR 999/4885RECQL 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.